Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About

Johnson & Johnson (JNJ) reached a proposed $5.5 billion settlement to resolve thousands of talc-related lawsuits, removing a significant legal overhang that has weighed on the stock. The company has also gained FDA clearance for its Ottava surgical robot and announced its 64th consecutive annual dividend increase. JNJ shares are up 28% year-to-date as the company targets $100 billion in revenue.

The talc settlement represents the most material catalyst for the stock, as it potentially eliminates years of litigation risk that has clouded investor sentiment. The FDA clearance for Ottava positions JNJ to compete in the growing surgical robotics market, while the dividend streak underscores the company's cash generation and commitment to shareholder returns.

JNJ's diversified product portfolio across pharmaceuticals, medical devices, and consumer health continues to drive resilience. The combination of removing legal risk, expanding into high-growth robotics, and maintaining strong fundamentals supports the company's path toward its $100 billion revenue target.